Intricacies for Posttranslational Tumor-Targeted Cytokine Gene Therapy
Figure 3
Tumor-targeting-mediated improvement of IL15-induced antitumor efficacy depends on the tumor histotype. (a) Diagrammatic representation of the IL15 plasmid with the IL15-coding region in the “Cytokine” region. The blue arrows represent the VNTANST-coding sequence insertion site in the plasmid DNA. CMV: cytomegalovirus promoter; IVS: intron; pA: bovine growth hormone polyadenylation signal; STOP: stop codon. (b) Equivalent inhibition of K7M3 lung metastases from wtIL15 and ttIL15 pDNA treatments (treatments on days 0 and 7). Inhibition of primary tumor growth (c) and metastatic lung tumor development (d) by ttIL15 pDNA compared to wtIL15 pDNA. Black arrows represent treatments. # represents compared to all other groups.
